Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
70.27 ^USD	+0.09%		+2.20%	+11.89%

May. 22	Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing	MT
May. 14	Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing	May. 22
Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM	May. 14
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update	May. 08
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	Apr. 25
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	Apr. 22
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	Mar. 30
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	Mar. 21
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating	Mar. 12
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	Mar. 12
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	Mar. 04
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	Mar. 04
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating	Feb. 28
Vaxcyte Q4 Loss Widens	Feb. 27
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Other languages

Filters